Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 02, 2022

SELL
$3.17 - $6.17 $209,806 - $408,361
-66,185 Closed
0 $0
Q1 2022

May 10, 2022

BUY
$4.16 - $13.72 $4,380 - $14,447
1,053 Added 1.62%
66,185 $357,000
Q4 2021

Feb 14, 2022

BUY
$10.83 - $18.41 $13,212 - $22,460
1,220 Added 1.91%
65,132 $880,000
Q3 2021

Nov 03, 2021

BUY
$13.07 - $18.84 $28,218 - $40,675
2,159 Added 3.5%
63,912 $1.15 Million
Q2 2021

Aug 13, 2021

SELL
$16.52 - $20.4 $29,736 - $36,720
-1,800 Reduced 2.83%
61,753 $1.06 Million
Q1 2021

May 03, 2021

SELL
$16.56 - $25.46 $2,649 - $4,073
-160 Reduced 0.25%
63,553 $1.27 Million
Q4 2020

Feb 02, 2021

BUY
$15.77 - $19.03 $2,523 - $3,044
160 Added 0.25%
63,713 $1.08 Million
Q3 2020

Nov 04, 2020

SELL
$16.59 - $24.79 $995 - $1,487
-60 Reduced 0.09%
63,553 $1.05 Million
Q2 2020

Aug 07, 2020

SELL
$16.86 - $23.44 $95,764 - $133,139
-5,680 Reduced 8.2%
63,613 $1.47 Million
Q1 2020

May 13, 2020

BUY
$14.47 - $27.96 $416,591 - $804,968
28,790 Added 71.08%
69,293 $1.24 Million
Q4 2019

Feb 12, 2020

BUY
$15.87 - $23.12 $5,554 - $8,092
350 Added 0.87%
40,503 $874,000
Q3 2019

Nov 07, 2019

SELL
$16.91 - $36.27 $1.58 Million - $3.4 Million
-93,641 Reduced 69.99%
40,153 $731,000
Q2 2019

Aug 23, 2019

BUY
$31.0 - $36.3 $591,790 - $692,967
19,090 Added 16.64%
133,794 $4.76 Million
Q1 2019

Aug 07, 2019

SELL
$31.58 - $46.35 $9,505 - $13,951
-301 Reduced 0.26%
114,704 $3.85 Million
Q4 2018

Aug 07, 2019

BUY
$30.43 - $56.65 $42,662 - $79,423
1,402 Added 1.23%
115,005 $3.78 Million
Q3 2018

Aug 07, 2019

BUY
$46.46 - $68.49 $3.64 Million - $5.37 Million
78,427 Added 222.96%
113,603 $6.93 Million
Q2 2018

Aug 07, 2019

BUY
$46.25 - $104.45 $1.63 Million - $3.67 Million
35,176 New
35,176 $1.72 Million

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $139M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Treasurer Of The State Of North Carolina Portfolio

Follow Treasurer Of The State Of North Carolina and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Treasurer Of The State Of North Carolina, based on Form 13F filings with the SEC.

News

Stay updated on Treasurer Of The State Of North Carolina with notifications on news.